Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras(G12D/+);Tp53(R172H/+) (KPC) mice, a genetically engineered model of pancreatic cancer

PURPOSE: Metarrestin is a first-in-class small molecule clinical candidate capable of disrupting the perinucleolar compartment, a subnuclear structure unique to metastatic cancer cells. This study aims to define the pharmacokinetic (PK) profile of metarrestin and the pharmacokinetic/pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilimas, Tomas, Wang, Amy Q., Patnaik, Samarjit, Hughes, Emma A., Singleton, Marc D., Knotts, Zachary, Li, Dandan, Frankowski, Kevin, Schlomer, Jerome J., Guerin, Theresa M., Springer, Stephanie, Drennan, Catherine, Dextras, Christopher, Wang, Chen, Gilbert, Debra, Southall, Noel, Ferrer, Marc, Huang, Sui, Kozlov, Serguei, Marugan, Juan, Xu, Xin, Rudloff, Udo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267684/
https://www.ncbi.nlm.nih.gov/pubmed/30306263
http://dx.doi.org/10.1007/s00280-018-3699-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267684/
https://www.ncbi.nlm.nih.gov/pubmed/30306263
http://dx.doi.org/10.1007/s00280-018-3699-0

Ejemplares similares